Barbara M. Wirostko MD

Glaucoma Related, Retinal Disease

Physician

65 S Mario Capecchi DrSalt Lake City, UT 84132
Phone+1 801-581-2352

Dr. Wirostko is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wirostko's full profile Already have an account?

Summary

Dr. Barbara Wirostko is fellow of AAO and ARVO and a glaucoma fellowship trained ophthalmologist practicing in Park City, UT. She received her medical degree from Columbia University College of Physicians & Surgeons, fellowship at Cornell University and has been in practice 26 years. Prior to joining the University of Utah, she served as Senior Global Medical Director at Pfizer, overseeing glaucoma clinical research and the Xalatan franchise. She specializes in glaucoma related diseases and is experienced in glaucoma related disorders, glaucoma epidemiology, general / comprehensive ophthalmology, pediatric glaucoma, drug development, pseudoexfoliation, and minimally invasive glaucoma surgery. She is a serial entrepreneur and currently serves as Chief Medical Officer and coFounder of Qlaris Bio (MA) a company developing ophthalmic therapeutics for unmet ocular needs.

Education & Training

New York Presbyterian Hospital (Columbia and Cornell Campus)Fellowship, Glaucoma, 1995 - 1996
New York Presbyterian Hospital (Columbia Campus)Residency, Ophthalmology, 1992 - 1995
Hackensack University Medical Center (Palisades)Internship, Transitional Year, 1991 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1991
Cornell UniversityB.A., Microbiology, with Distinction, 1987

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

UT State Medical License 2010 - 2028
NY State Medical License 1992 - 2010
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
UNKNOWN
PHASE1, PHASE2
Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK") Start of enrollment: 2019 Jun 25
COMPLETED
NA

Publications & Presentations

PubMed

What Does the US Food and Drug Administration Regulation of Portable Perimeters Mean?
Charissa H Tan, Elvin Y Ng, Malvina B Eydelman, Barbara M Wirostko, Brian C Stagg
Ophthalmology. Glaucoma. 2026-08-11
Preclinical Evaluation of Safety and Efficacy of QLS-111: A Novel Formulation of an Adenosine Triphosphate-Sensitive Potassium Channel Opener.
Barbara M Wirostko, Uttio Roy Chowdhury, Lisa A Brandano, Ralph A Casale, Daniel J DeWalt
Ophthalmology Science. 2026-04-01
Bench to bedside: Bridging the gap.
Cynthia L Steel, Barbara M Wirostko
Indian Journal of Ophthalmology. 2026-02-01

Journal Articles

Association of Exfoliation Syndrome with Risk of Indirect Inguinal HerniaThe Utah Project on Exfoliation Syndrome
R Rand Allingham, Barbara M Wirostko, Robert Ritch, JAMA
Ophthalmic Uses of a Thiol-Modified Hyaluronan-Based Hydrogel
Wirostko B, Mann B, Williams D. Prestwich G, Advanced Wound Care, 1/1/2014
Thiolated hyaluronan-based hydrogels crosslinked using oxidized glutathione: an injectable matrix designed for ophthalmic applications
Zarembinski T, Doty NJ, Erickson IE, Srinivas R, Wirostko BM, Tew WP, Acta Biomater, 1/1/2014

Lectures

Delivery of Human Growth Hormone via DSM's Poly(ester amide)
Seattle, WA - 1/1/2013
Corneal Wound Healing Model in New Zealand White Rabbits for Evaluating Persistent Corneal Epithelial Defects
Seattle, WA - 1/1/2013
Hystem, a bio-absorbable protein delivery polymer: safety, and efficacy in a corneal debridement model
Seattle, WA - 1/1/2013

Press Mentions

Qlaris Bio Announces Positive Topline Data from Two Phase 2 Trials of QLS-111 for GlaucomaFebruary 7th, 2024
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101May 18th, 2022
Qlaris Bio Commences Enrolment in Glaucoma Therapy TrialApril 16th, 2021